# Ritivel -- Paul Graham Evaluation

The first thing I notice about Ritivel is how many well-funded competitors are already here. Yseop has powered 150+ clinical trials and made TIME's Best Inventions list. Deep Intelligent Pharma has raised $110M+. Certara is a public company that launched CoAuthor two years ago. McKinsey co-developed an AI CSR platform *with Merck* that already cut first-draft time in half. When I see a pre-seed company entering a space where McKinsey is building alongside a top-five pharma company, I don't think "opportunity" -- I think "consensus." The most dangerous startup ideas are the ones everyone already agrees are good, because the competition has already been priced in. This looks less like a hidden problem and more like a problem that's already being solved by people with deeper pockets and existing pharma relationships.

The origin of this idea concerns me more than the competition does. How did three engineers in their mid-twenties -- one from a data pipeline company, one from management consulting, one from academia -- find regulatory medical writing? The dossier tells us: "50+ conversations with pharma professionals." That's customer discovery, which business schools teach. It is not the same thing as organic problem discovery. Drew Houston didn't conduct 50 conversations about file synchronization -- he kept forgetting his USB drive. The Collison brothers didn't interview payment processors -- they were programmers who couldn't believe how hard it was to accept payments online. When a founder's connection to the problem is "we talked to people who have this problem," the idea is manufactured. It emerged from a search for a startup to build, not from a problem the founders couldn't stop thinking about. None of these founders have spent a single day inside a pharma regulatory writing team. They haven't lived with the 180-hour CSR authoring cycle. They haven't chased colleagues for clinical data inputs at midnight before an FDA deadline. The problem is real, but it isn't theirs.

I'll grant that the schlep here is genuine and substantial. FDA formatting requirements, ICH guidelines, word-level citation traceability, local deployment with zero data retention, Veeva and SharePoint integrations -- this is the kind of tedious, regulatory complexity that scares people away. In principle, that's exactly what I look for. The problem with Ritivel isn't that the schlep doesn't exist. It's that the schlep hasn't scared people away. It's attracted $130M+ in competitor funding. When schlep blindness works as a moat, it's because nobody else *sees* the opportunity. Here, everybody sees it. The regulatory writing automation space is not hiding in plain sight -- it's standing under a spotlight.

The strongest bull case for Ritivel is this: the technical team is genuinely capable, and incumbents might be doing it wrong. Pavan's NeurIPS publication on text-to-SQL and his SIGMOD work sit squarely at the intersection of structured data parsing and document generation -- exactly what regulatory writing automation requires. Nirmit has real ML engineering projects, not just coursework. If these founders have built a product that generates more accurate, better-cited first drafts than Yseop's NLG approach or Certara's template-based CoAuthor, they could win despite being late and small. The local-deployment architecture shows they understand pharma's security constraints at a level that suggests more than surface research. And the word-level citation feature -- linking every claim back to its source document -- addresses the core trust problem in AI-generated regulatory content. If I could see one pharma company that tried Ritivel alongside Certara's CoAuthor and preferred Ritivel, that would change this analysis considerably. But I can't see that. I see conversations, not conversions.

The team structure has a familiar shape that I don't love at this stage. Gunin Gupta's background is management consulting at Kearney -- no technical contribution, no pharma domain expertise. The YC description claims all three founders "previously built AI copilots at Microsoft Research," but public sources only partially confirm this for two of three founders and don't confirm it at all for Gunin. When a founding team's shared backstory doesn't fully check out, it raises the question of whether the co-founder relationships are deep enough to survive the pressure. I don't know the answer, but the question is there. What I do know is that at pre-seed, a three-person team entering pharma enterprise sales needs every person building product or bringing domain relationships. A consulting background brings neither to regulatory document automation.

This is smart people choosing a large, obvious market and applying genuine technical talent to it. That's not nothing. But it's the pattern I've seen fail more often than succeed. The founders who win in regulated enterprise markets are usually the ones who spent years inside those enterprises and left because they couldn't stand the inefficiency anymore. They bring relationships, intuition about buyer psychology, and the kind of domain knowledge that no amount of customer interviews can replicate. Ritivel's founders are learning the domain from the outside. Against competitors who have already shipped products and closed pharma customers, that learning curve is a serious disadvantage.

### Dimension Scores

| Criterion | Score |
|-----------|-------|
| Organic Problem Discovery and Schlep Willingness | 8/30 |
| Relentlessly Resourceful Founders | 12/25 |
| Evidence of Wanting: Demonstrated User Pull | 5/20 |
| Technical Hacker Founders Who Build | 10/15 |
| Growth Trajectory and Default Alive Economics | 5/10 |
| **Total** | **40/100** |

**Total Score: 40/100** (Pass)
